GlassScriptPhysician profile
Byung Chan Thomas Ahn
NPI 1962701219
$4,756.80
in general payments reported to CMS, 2019-2025
37 companies · $1,451 in 2025
The $1,451 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $104 · 2021: $84.45 · 2022: $432 · 2023: $1,328 · 2024: $1,357 · 2025: $1,451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,124 · Education: $12.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,124.34 |
| Education | $12.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $817.32 | 2022-2025 | Briviact, Zilbrysq, Fintepla |
| Abbvie INC. | $759.45 | 2022-2025 | Ubrelvy, Qulipta, Botox |
| Neurocrine Biosciences, INC. | $451.13 | 2022-2025 | Ingrezza, Ongentys |
| Celgene Corporation | $413.12 | 2022-2024 | Zeposia |
| Pfizer INC. | $265.52 | 2022-2025 | |
| Biogen, INC. | $245.69 | 2021-2025 | Tysabri, Vumerity, Spinraza |
| Impel Pharmaceuticals INC. | $199.04 | 2023 | Trudhesa |
| Merz Pharmaceuticals, LLC | $139.50 | 2022 | |
| Allergan, INC. | $121.60 | 2019-2021 | |
| Lundbeck LLC | $111.92 | 2023-2025 | Vyepti, Rexulti |
| Teva Pharmaceuticals USA, INC. | $105.80 | 2024-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Catalyst Pharmaceuticals, INC. | $103.88 | 2023-2025 | Fycompa |
| Sk Life Science, INC. | $84.52 | 2023-2025 | |
| Amgen INC. | $81.98 | 2022-2024 | Uplizna |
| Mdd US Operations, LLC | $81.44 | 2025 | Gocovri, Qelbree |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $81.05 | 2021-2023 | Hizentra |
| Neurelis, INC. | $69.17 | 2024-2025 | Valtoco |
| Otsuka America Pharmaceutical, INC. | $66.70 | 2023-2025 | Rexulti, Nuedexta |
| Genentech USA, INC. | $65.61 | 2023 | Enspryng, Ocrevus |
| Argenx US, INC. | $64.92 | 2023-2025 | Vyvgart Hytrulo |
| Boston Scientific Corporation | $39.17 | 2025 | General - Dbs |
| Amneal Pharmaceuticals LLC | $37.68 | 2023-2024 | Rytary |
| Abbott Laboratories | $32.24 | 2023-2025 | Amplatzer Talisman, Proclaim |
| Avadel Cns Pharmaceuticals, LLC | $32.04 | 2025 | Lumryz |
| Vanda Pharmaceuticals INC. | $30.72 | 2025 | Ponvory |
| Alexion Pharmaceuticals, INC. | $27.46 | 2022-2025 | Ultomiris |
| Jazz Pharmaceuticals INC. | $27.18 | 2025 | |
| Sumitomo Pharma America, INC. | $25.45 | 2023-2024 | Aptiom |
| Microtransponder, INC. | $23.74 | 2025 | |
| Novartis Pharmaceuticals Corporation | $22.33 | 2025 | |
| Averitas Pharma INC. | $21.79 | 2023 | Qutenza |
| Ani Pharmaceuticals, INC. | $21.29 | 2024 | Purified Cortrophin Gel |
| Tersera Therapeutics LLC | $19.27 | 2025 | Quzyttir |
| Janssen Biotech, INC. | $18.51 | 2025 | |
| Octapharma USA, INC. | $18.05 | 2023 | Panzyga |
| Livanova USA, INC. | $16.44 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Grifols USA, LLC | $14.08 | 2025 | Gamunex-C |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Byung Chan Ahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.